

SR Pharma plc ("SR Pharma" or "the Company")

Ordinary Shares of 1p each

London 12 July 2005 – Following the completion of the acquisition, announced yesterday, of approximately 96 per cent. of Atugen AG acquired through the issue of SR Pharma Ordinary Shares, the Company now announces that the following shareholders have an interest in 3 per cent. or more of the enlarged issued share capital of the Company:

Shareholder	Number of shares	Percentage of issued capital
Apax Europe IV – A LP	12,306,993	26.35%
MPM Asset Management 1998 LLC	3,440,959	7.37%
Novartis Forschungsstiftung	2,962,505	6.34%
Technologie-Beteiligungs- Gesellschaft mbh	2,869,400	6.14%
Bank von Ernst & Cie	2,769,284	5.93%
J L Stanford	2,169,000	4.64%
G A W Rook	1,510,000	3.23%

In addition, SR Pharma's Non-executive Director Jeremy Curnock Cook is a director and a substantial shareholder of Bioscience Managers Limited which holds 604,398 Ordinary Shares representing 1.30 per cent. of the Company's enlarged issued share capital.

Further information:

Melvyn Davies
Company Secretary
SR Pharma plc

Tel: 020 7307 1620